Status:
TERMINATED
Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
Lead Sponsor:
Xemed LLC
Collaborating Sponsors:
University of Pennsylvania
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18-85 years
Phase:
PHASE1
Brief Summary
Cancer radiation treatment plans that employ lung functional avoidance methods require 3D maps that differentiate regions of healthy lung function from regions of compromised tissue to deliver suffici...
Detailed Description
Customized 3D planning of radiation therapy for lung cancer delivers a lethal dose to the tumor region while avoiding important structures (spine) and organs (esophagus, heart, lungs). Since radiation...
Eligibility Criteria
Inclusion
- Patients over 18 years with a diagnosis of non-small lung cancer and planned for a definitive course of radiation therapy.
- Preferred patients will have had successful radiation therapy for a prior lung cancer and developed a secondary lung cancer for which are to be treated.
- Other de-nuovo lung cancer patients planned for radiation therapy with lung heterogeneity from natural co-morbidities (e.g., COPD stage 3+).
Exclusion
- Patients less than 18 years old
- Patients known to be pregnant - a positive pregnancy test will be used to respectively exclude pregnant patients,
- Any known contraindication to MRI examination
- Anyone with an implanted metal device
- Inability to provide informed consent
- A language, communication, cognitive or behavioral impairment that might interfere with fully informed participation in the study.
- History of uncompensated organ failure (i.e. organ failure that is not stabilized through medical intervention), which will be assessed by the PI.
- Homelessness or other unstable living situation
- Active drug or alcohol dependence
- Claustrophobia
- Subjects weighting more than 300 pounds.
- Subjects with chest size larger than the bore of MRI machine can accommodate
Key Trial Info
Start Date :
March 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2024
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT05302817
Start Date
March 17 2023
End Date
December 10 2024
Last Update
March 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104